pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 2·1 min read
save

Loss of Colorado Rep. Diana DeGette removes a knowledgeable voice for biopharma in Congress

Jul 2, 2026·read at STAT ↗Negative

Colorado Democratic Rep. Diana DeGette was defeated in her primary, ending her service in the U.S. House of Representatives.

DeGette was widely recognized for her deep understanding of biopharma policy, frequently serving as a resource for industry stakeholders even though she was not always an outspoken supporter.

Her departure means the drug industry loses a familiar congressional ally, potentially complicating advocacy efforts as other lawmakers adjust to fill the expertise gap.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: What does DeGette’s loss mean for pharma?”

read at STAT ↗
419 words · retrieved Jul 2
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ROCHE
topics
KRASNSCLCOncologyPulmonology

related stories

  • Sep 28Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitorBioSpace
  • Sep 15WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlightBioPharma Dive
  • Sep 145 drugmakers chasing Merck and Moderna in the cancer vaccine raceBioSpace
  • Sep 3GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer assetFierce Biotech
  • Aug 26Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debateFierce Biotech